




Supplementary Figure 1: Flt3L increases DC numbers and potentiates their activation.





Supplementary Figure 2: naPRRa-activated DCs prime patient T cells.




Supplementary Figure 3: naPRRa-activated DCs cross-prime OT-I T cells.



Supplementary Figure 4: naPRRa-activated DCs cross-present tumor-derived antigen to T cells.

Supplementary Figure 5: Identifying unique activation profiles of naPRRa.

Supplementary Figure 6: Rational combination identifies the naPRRa triplet B/P/R that promotes anti-tumor immunity.

Supplementary Figure 7: The naPRRa triplet B/P/R that promotes anti-tumor immunity in ISV against 4T1 mammary carcinoma.

